Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2013

01-06-2013 | NON-THEMATIC REVIEW

Stromal cells in tumor microenvironment and breast cancer

Authors: Yan Mao, Evan T. Keller, David H. Garfield, Kunwei Shen, Jianhua Wang

Published in: Cancer and Metastasis Reviews | Issue 1-2/2013

Login to get access

Abstract

Cancer is a systemic disease encompassing multiple components of both tumor cells themselves and host stromal cells. It is now clear that stromal cells in the tumor microenvironment play an important role in cancer development. Molecular events through which reactive stromal cells affect cancer cells can be defined so that biomarkers and therapeutic targets can be identified. Cancer-associated fibroblasts (CAFs) make up the bulk of cancer stroma and affect the tumor microenvironment such that they promote cancer initiation, angiogenesis, invasion, and metastasis. In breast cancer, CAFs not only promote tumor progression but also induce therapeutic resistance. Accordingly, targeting CAFs provides a novel way to control tumors with therapeutic resistance. This review summarizes the current understandings of tumor stroma in breast cancer with a particular emphasis on the role of CAFs and the therapeutic implications of CAFs. In addition, the effects of other stromal components such as endothelial cells, macrophages, and adipocytes in breast cancer are also discussed. Finally, we describe the biologic markers to categorize patients into a specific and confirmed subtype for personalized treatment.
Literature
1.
Siegel, R., et al. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62(1), 10–29.CrossRef
2.
Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98–101.PubMed
3.
4.
Ostman, A., et al. (2009). Cancer-associated fibroblasts and tumor growth—bystanders turning into key players. Current Opinion in Genetics and Development, 19(1), 67–73.PubMedCrossRef
5.
Loeffler, M., et al. (2006). Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. The Journal of Clinical Investigation, 116(7), 1955–1962.PubMedCrossRef
6.
Gabbiani, G., et al. (1971). Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia, 27(5), 549–550.PubMedCrossRef
7.
Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine, 315(26), 1650–1659.PubMedCrossRef
8.
Kojima, Y., et al. (2010). Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 107(46), 20009–20014.PubMedCrossRef
9.
Moskovits, N., et al. (2006). p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Research, 66(22), 10671–10676.PubMedCrossRef
10.
Aboussekhra, A. (2011). Role of cancer-associated fibroblasts in breast cancer development and prognosis. International Journal of Developmental Biology, 55(7–9), 841–849.PubMedCrossRef
11.
Kiaris, H., et al. (2005). Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Research, 65(5), 1627–1630.PubMedCrossRef
12.
Trimis, G., et al. (2008). Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Human Molecular Genetics, 17(22), 3596–3600.PubMedCrossRef
13.
Trimboli, A. J., et al. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 461(7267), 1084–1091.PubMedCrossRef
14.
Trimmer, C., et al. (2011). Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biology & Therapy, 11(4), 383–394.CrossRef
15.
Hill, R., et al. (2005). Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell, 123(6), 1001–1011.PubMedCrossRef
16.
Spaeth, E. L., et al. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One, 4(4), e4992.PubMedCrossRef
17.
Jotzu, C., et al. (2010). Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Analytical Cellular Pathology (Amsterdam), 33(2), 61–79.
18.
Zeisberg, E. M., et al. (2007). Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Research, 67(21), 10123–10128.PubMedCrossRef
19.
Garin-Chesa, P., et al. (1990). Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proceedings of the National Academy of Sciences of the United States of America, 87(18), 7235–7239.PubMedCrossRef
20.
Erez, N., et al. (2010). Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell, 17(2), 135–147.PubMedCrossRef
21.
Mercier, I., et al. (2008). Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biology & Therapy, 7(8), 1212–1225.CrossRef
22.
Sugimoto, H., et al. (2006). Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biology & Therapy, 5(12), 1640–1646.CrossRef
23.
Perou, C. M., et al. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752.PubMedCrossRef
24.
Haque, R., et al. (2012). PS1-05: disparities in breast cancer survival by molecular subtype and race/ethnicity. Clinical Medicine & Research, 10(3), 145.CrossRef
25.
Onitilo, A. A., et al. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical Medicine & Research, 7(1–2), 4–13.CrossRef
26.
Martinez-Outschoorn, U. E., et al. (2010). Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle, 9(12), 2423–2433.PubMedCrossRef
27.
Lohr, M., et al. (2001). Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Research, 61(2), 550–555.PubMed
28.
Bronzert, D. A., et al. (1987). Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 84(16), 5763–5767.PubMedCrossRef
29.
Shao, Z. M., et al. (2000). Human breast carcinoma desmoplasia is PDGF initiated. Oncogene, 19(38), 4337–4345.PubMedCrossRef
30.
Strutz, F., et al. (2000). Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney International, 57(4), 1521–1538.PubMedCrossRef
31.
Giannoni, E., et al. (2010). Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial–mesenchymal transition and cancer stemness. Cancer Research, 70(17), 6945–6956.PubMedCrossRef
32.
Hugo, H. J., et al. (2012). Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenvironment. doi:10.​1007/​s12307-012-0098-7
33.
Koleske, A. J., et al. (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proceedings of the National Academy of Sciences of the United States of America, 92(5), 1381–1385.PubMedCrossRef
34.
Martinez-Outschoorn, U. E., et al. (2010). Oxidative stress in cancer associated fibroblasts drives tumor–stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle, 9(16), 3256–3276.PubMedCrossRef
35.
36.
Serrano, M., et al. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366(6456), 704–707.PubMedCrossRef
37.
Ohtani, N., et al. (2004). The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. The Journal of Medical Investigation, 51(3–4), 146–153.PubMedCrossRef
38.
Matros, E., et al. (2005). BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Research and Treatment, 91(2), 179–186.PubMedCrossRef
39.
Hasebe, T., et al. (2001). Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Modern Pathology, 14(4), 325–337.PubMedCrossRef
40.
Orimo, A., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3), 335–348.PubMedCrossRef
41.
Saito, R. A., et al. (2010). Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Research, 70(7), 2644–2654.PubMedCrossRef
42.
Zhang, C., et al. (2009). Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clinical Cancer Research, 15(12), 4017–4027.PubMedCrossRef
43.
Shekhar, M. P., et al. (2001). Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Research, 61(4), 1320–1326.PubMed
44.
Sadlonova, A., et al. (2005). Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Research, 7(1), R46–R59.PubMedCrossRef
45.
Adams, E. F., et al. (1988). Effects of human breast fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of MCF-7 cells in culture. Breast Cancer Research and Treatment, 11(2), 165–172.PubMedCrossRef
46.
Stuelten, C. H., et al. (2010). Transient tumor–fibroblast interactions increase tumor cell malignancy by a TGF-beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One, 5(3), e9832.PubMedCrossRef
47.
Hu, M., et al. (2009). Role of COX-2 in epithelial–stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3372–3377.PubMedCrossRef
48.
Hu, M., et al. (2008). Regulation of in situ to invasive breast carcinoma transition. Cancer Cell, 13(5), 394–406.PubMedCrossRef
49.
Tsuyada, A., et al. (2012). CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Research, 72(11), 2768–2779.PubMedCrossRef
50.
Qian, B. Z., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222–225.PubMedCrossRef
51.
Tan, W., et al. (2011). Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature, 470(7335), 548–553.PubMedCrossRef
52.
Rossi, D., et al. (2000). The biology of chemokines and their receptors. Annual Review of Immunology, 18, 217–242.PubMedCrossRef
53.
Roodman, G. D. (2004). Mechanisms of bone metastasis. The New England Journal of Medicine, 350(16), 1655–1664.PubMedCrossRef
54.
Azim, H. A., et al. (2012). Bone metastasis in breast cancer: the story of RANK-ligand. Journal of the Egyptian National Cancer Institute, 24(3), 107–114.PubMedCrossRef
55.
Chen, J., et al. (2011). CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell, 19(4), 541–555.PubMedCrossRef
56.
Campbell, I., et al. (2009). Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Research, 69(17), 6765–6768. discussion 6769.PubMedCrossRef
57.
Hu, M., et al. (2005). Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genetics, 37(8), 899–905.PubMedCrossRef
58.
Allinen, M., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6(1), 17–32.PubMedCrossRef
59.
Enkelmann, A., et al. (2011). Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. Journal of Cancer Research and Clinical Oncology, 137(5), 751–759.PubMedCrossRef
60.
Fiegl, H., et al. (2006). Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Research, 66(1), 29–33.PubMedCrossRef
61.
Jiang, L., et al. (2008). Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Research, 68(23), 9900–9908.PubMedCrossRef
62.
Yu, J., et al. (2012). Unlike pancreatic cancer cells pancreatic cancer associated fibroblasts display minimal gene induction after 5-aza-2′-deoxycytidine. PLoS One, 7(9), e43456.PubMedCrossRef
63.
Robinson, C. M., et al. (2012). Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respiratory Research, 13(1), 74.PubMedCrossRef
64.
Knower, K. C., et al. (2010). Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts. Molecular and Cellular Endocrinology, 321(2), 123–130.PubMedCrossRef
65.
Tyan, S. W., et al. (2012). Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. PLoS One, 7(4), e35128.PubMedCrossRef
66.
Gangaraju, V. K., et al. (2009). MicroRNAs: key regulators of stem cells. Nature Reviews Molecular Cell Biology, 10(2), 116–125.PubMedCrossRef
67.
Fazi, F., et al. (2008). MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovascular Research, 79(4), 553–561.PubMedCrossRef
68.
Leung, A. K., et al. (2006). Function and localization of microRNAs in mammalian cells. Cold Spring Harbor Symposia on Quantitative Biology, 71, 29–38.PubMedCrossRef
69.
Tiscornia, G., et al. (2010). MicroRNAs in embryonic stem cell function and fate. Genes & Development, 24(24), 2732–2741.CrossRef
70.
Davis-Dusenbery, B. N., et al. (2010). MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer, 1(11), 1100–1114.PubMedCrossRef
71.
Farazi, T. A., et al. (2011). MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Research, 71(13), 4443–4453.PubMedCrossRef
72.
Iliopoulos, D., et al. (2009). An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell, 139(4), 693–706.PubMedCrossRef
73.
Iliopoulos, D., et al. (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Molecular Cell, 39(4), 493–506.PubMedCrossRef
74.
Iorio, M. V., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065–7070.PubMedCrossRef
75.
Jazbutyte, V., et al. (2010). MicroRNA-21: from cancer to cardiovascular disease. Current Drug Targets, 11(8), 926–935.PubMedCrossRef
76.
Qian, B., et al. (2009). High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Research and Treatment, 117(1), 131–140.PubMedCrossRef
77.
Aprelikova, O., et al. (2012). Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. doi:10.​1038/​onc.​2012.​351
78.
Aprelikova, O., et al. (2010). The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle, 9(21), 4387–4398.PubMedCrossRef
79.
Musumeci, M., et al. (2010). Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene, 30(41), 4231–4242.CrossRef
80.
Martinez-Outschoorn, U. E., et al. (2011). Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biology & Therapy, 12(10), 924–938.CrossRef
81.
Sun, Y., et al. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Medicine. doi:10.​1038/​nm.​2890
82.
Tchou, J., et al. (2012). Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Advances in Pharmacology, 65, 45–61.PubMedCrossRef
83.
Davies, C., et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771–784.PubMed
84.
Shekhar, M. P., et al. (2007). Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. American Journal of Pathology, 170(5), 1546–1560.PubMedCrossRef
85.
Pontiggia, O., et al. (2012). The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Research and Treatment, 133(2), 459–471.PubMedCrossRef
86.
Mueller, K. L., et al. (2012). Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Research, 14(4), R104.PubMedCrossRef
87.
Johansson, A. C., et al. (2012). Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Molecular Cancer Research, 10(9), 1158–1168.PubMedCrossRef
88.
Dittmer, A., et al. (2011). Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. International Journal of Oncology, 39(3), 689–696.PubMed
89.
Capparelli, C., et al. (2012). CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle, 11(19).
90.
Bergamaschi, A., et al. (2008). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. The Journal of Pathology, 214(3), 357–367.PubMedCrossRef
91.
Finak, G., et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine, 14(5), 518–527.PubMedCrossRef
92.
Sloan, E. K., et al. (2009). Stromal cell expression of caveolin-1 predicts outcome in breast cancer. American Journal of Pathology, 174(6), 2035–2043.PubMedCrossRef
93.
Pavlides, S., et al. (2009). The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle, 8(23), 3984–4001.PubMedCrossRef
94.
Farmer, P., et al. (2009). A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 15(1), 68–74.PubMedCrossRef
95.
Ahn, S., et al. (2012). The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biology, 33, 1573–1580.
96.
Martinet, L., et al. (2011). Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Research, 71(17), 5678–5687.PubMedCrossRef
97.
DeNardo, D. G., et al. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1(1), 54–67.PubMedCrossRef
98.
Laoui, D., et al. (2011). Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. International Journal of Developmental Biology, 55(7–9), 861–867.PubMedCrossRef
99.
Lee, A. H., et al. (1997). Angiogenesis and inflammation in invasive carcinoma of the breast. Journal of Clinical Pathology, 50(8), 669–673.PubMedCrossRef
100.
Campbell, M. J., et al. (2011). Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment, 128(3), 703–711.PubMedCrossRef
101.
Leek, R. D., et al. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Research, 56(20), 4625–4629.PubMed
102.
Lewis, C. E., et al. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66(2), 605–612.PubMedCrossRef
103.
Lewis, J. S., et al. (2000). Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. The Journal of Pathology, 192(2), 150–158.PubMedCrossRef
104.
Dirkx, A. E., et al. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183–1196.PubMedCrossRef
105.
Roland, C. L., et al. (2009). Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Molecular Cancer Therapeutics, 8(7), 1761–1771.PubMedCrossRef
106.
Melani, C., et al. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67(23), 11438–11446.PubMedCrossRef
107.
Lin, E. Y., et al. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of Experimental Medicine, 193(6), 727–740.PubMedCrossRef
108.
Oosterling, S. J., et al. (2005). Macrophages direct tumour histology and clinical outcome in a colon cancer model. The Journal of Pathology, 207(2), 147–155.PubMedCrossRef
109.
Mukhtar, R. A., et al. (2011). Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Review of Molecular Diagnostics, 11(1), 91–100.PubMedCrossRef
110.
Nilsson, S., et al. (2012). Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One, 7(4), e36051.PubMedCrossRef
111.
Yang, M., et al. (2011). Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Molecular Cancer, 10, 117.PubMedCrossRef
112.
Hiraoka, K., et al. (2008). Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Science, 99(8), 1595–1602.PubMedCrossRef
113.
Gazzaniga, S., et al. (2007). Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. The Journal of Investigative Dermatology, 127(8), 2031–2041.PubMedCrossRef
114.
Zeisberger, S. M., et al. (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer, 95(3), 272–281.PubMedCrossRef
115.
Zhang, W., et al. (2010). Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clinical Cancer Research, 16(13), 3420–3430.PubMedCrossRef
116.
Veltman, J. D., et al. (2010). Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. British Journal of Cancer, 103(5), 629–641.PubMedCrossRef
117.
Luckman, S. P., et al. (1998). Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. Journal of Bone and Mineral Research, 13(11), 1668–1678.PubMedCrossRef
118.
Cecchini, M. G., et al. (1987). Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research, 2(2), 135–142.PubMedCrossRef
119.
Coscia, M., et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 14(12), 2803–2815.PubMedCrossRef
120.
Man, Y. G., et al. (2004). The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the “protease-centered” hypothesis. Experimental Cell Research, 301(2), 103–118.PubMedCrossRef
121.
Knutson, K. L., et al. (2006). IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. Journal of Immunology, 177(1), 84–91.
122.
Mahmoud, S. M., et al. (2011). Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology, 29(15), 1949–1955.PubMedCrossRef
123.
Ruffell, B., et al. (2012). Leukocyte composition of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 109(8), 2796–2801.PubMedCrossRef
124.
Acharyya, S., et al. (2011). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell, 150(1), 165–178.CrossRef
125.
Iyengar, P., et al. (2005). Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. The Journal of Clinical Investigation, 115(5), 1163–1176.PubMed
126.
Iyengar, P., et al. (2003). Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene, 22(41), 6408–6423.PubMedCrossRef
127.
Finley, D. S., et al. (2009). Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. Journal of Urology, 182(4), 1621–1627.PubMedCrossRef
128.
Yu, J. M., et al. (2008). Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells and Development, 17(3), 463–473.PubMedCrossRef
129.
Walter, M., et al. (2009). Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene, 28(30), 2745–2755.PubMedCrossRef
130.
Welte, G., et al. (2012). Interleukin-8 derived from local tissue-resident stromal cells promotes tumor cell invasion. Molecular Carcinogenesis, 51, 861–868.
131.
Pinilla, S., et al. (2009). Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Letters, 284(1), 80–85.PubMedCrossRef
132.
Devarajan, E., et al. (2011). Epithelial–mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. International Journal of Cancer, 131(5), 1023–1031.CrossRef
133.
Muehlberg, F. L., et al. (2009). Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis, 30(4), 589–597.PubMedCrossRef
134.
Bochet, L., et al. (2011). Cancer-associated adipocytes promotes breast tumor radioresistance. Biochemical and Biophysical Research Communications, 411(1), 102–106.PubMedCrossRef
135.
Ligibel, J. (2011). Obesity and breast cancer. Oncology (Williston Park, N.Y.), 25(11), 994–1000.
136.
Dirat, B., et al. (2010). Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocrine Development, 19, 45–52.PubMedCrossRef
137.
Harris, R. E., et al. (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17(2), 55–67.PubMedCrossRef
138.
Dougall, W. C., et al. (2012). Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clinical Cancer Research, 18(2), 326–335.PubMedCrossRef
Metadata
Title
Stromal cells in tumor microenvironment and breast cancer
Authors
Yan Mao
Evan T. Keller
David H. Garfield
Kunwei Shen
Jianhua Wang
Publication date
01-06-2013
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9415-3

Other articles of this Issue 1-2/2013

Cancer and Metastasis Reviews 1-2/2013 Go to the issue

Erratum

Erratum to: The role of pharmacogenomics in metastatic renal cell carcinoma

NON-THEMATIC REVIEW

The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis

OriginalPaper

Animal models of colorectal cancer

OriginalPaper

Animal models of leukemia: any closer to the real thing?

OriginalPaper

Reconstructing skin cancers using animal models

NON-THEMATIC REVIEW

Tackling hepatitis B virus-associated hepatocellular carcinoma—the future is now
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits